leisure time -WSS

leisure time

author：fashion 2025-09-28 23:49:23 - browse：18188

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Long Covid needs a new name — and a new frame

hotspot

explore

WSS

Amazon expands telehealth clinic nationwide

Pence says 'crackpot lawyers' told Trump what he wanted to hear

New safety details link Apellis eye drug to rare cases of blindness

Acelyrin, a rare IPO success, stumbles in its first big test

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Long Covid needs a new name — and a new frame

leisure time

leisure time

leisure time

Psychedelics group wrestles with new pharma identity

Mitch McConnell episode has important public health takeaway

23andMe had bad news about my health. I wish a person had delivered it

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Cancer drug shortages should be causing more outrage

Will the IRA bring competition to the biologics market?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

New weight loss drugs vying to be the next Wegovy or Mounjaro

Medical records are filled with copy

New Covid vaccine is recommended for everyone 6 months or older

leisure time

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Food makers to regulators: Ultra

Breakthrough Alzheimer’s drugs are inaccessible in rural states

New Covid vaccine is recommended for everyone 6 months or older

Amazon expands telehealth clinic nationwide

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

explore

Wikipedia

entertainment